Neurocrine Biosciences (NBIX) Announces First Presentation of New Two-Year Data From Phase 3 CAHtalyst® Adult Study

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy according to analysts. On April 22, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study exhibiting sustained, substantial reductions in glucocorticoid (GC) doses in adults with classic congenital adrenal hyperplasia treated with CRENESSITY®. Management reported that around 70% of patients attained GC doses within the physiologic range, with the data building upon the previously reported one-year results.

Presented at the American Association of Clinical Endocrinology 2026 Annual Meeting in Las Vegas, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) further reported that around 75% of patients originally taking dexamethasone transitioned off this treatment, allowing a more physiologic glucocorticoid regimen without compromising androgen control. It further stated that the findings bolster “durable efficacy and a favorable long‑term safety profile in the largest interventional trial to date conducted in classic congenital adrenal hyperplasia”.

In a separate development, RBC Capital cut the price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $176 from $177 and reaffirmed an Outperform rating on the shares as part of its broader research note previewing Q1 results in Biotech.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biopharmaceutical company with a focus on neuroscience. It is involved in the research and development, sale, and commercialization of pharmaceuticals that treat neuroendocrine, neurological, and neuropsychiatric disorders. The company’s product portfolio includes treatments for chorea associated with Huntington’s disease, tardive dyskinesia, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.